Welcome to BioSeeker Group!

Analytical Tool - Lung Cancer

Additional Information

Published Date Feb 21, 2012
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,100.00

Quick Overview

Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments.
Request free sample pages from Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of:
"Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2012*".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

*This software application is a searchable database reflects the most recent advances in the field of lung cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Lung Cancer

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Colorectal Cancer
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal R&D and business development. Learn More


Analytical Tool - Hematological Cancers
"Analytical Tool – Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Antibodies. Learn More


Triple Analysis: Melanoma, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More